Difelikefalin, a peripherally restricted, selective kappa opioid receptor agonist, relieved moderate to severity itching in patients with stage 3 to 5 CKD significantly better than placebo in a phase 2 trial.
Many healthcare workers on the front lines of the COVID-19 pandemic lack the needed patient-protective equipment, putting them at the highest risk of contracting the disease, Holly Kramer, MD, President of the National Kidney Foundation (NKF), said in a March 26 address to attendees of the organization’s first live-virtual Spring Clinical Meetings. “At no other…
Veverimer treats metabolic acidosis by binding and eliminating hydrochloric acid from the gastrointestinal tract without introducing unwanted sodium or potassium.
In diabetic patients with chronic kidney disease and metabolic acidosis, veverimer resulted in significantly greater improvement in serum bicarbonate levels at 52 weeks compared with placebo.
As part of its first live-virtual Spring Clinical Meetings, the National Kidney Foundation (NKF) today is presenting awards to specialists in nephrology “who most exemplify the relentless efforts of the foundation to enhance the lives of patients through action, education and accelerating change,” according to a press release issued by the organization. Here is a…
After implementation of the federal prospective payment system for dialysis services in 2011, use of thrombolytic agents declined within HD units but increased outside of HD units, a study found.
